Chinese drug iza-bren doubled the lung cancer survival window in a phase 3 trial. That is a real efficacy win for China oncology and puts lung cancer assets back on the licensing radar. Watch how fast

What happened: Sichuan Biokin Pharmaceutical's anticancer drug iza-bren was presented at the ESMO Congress in Madrid, showing a significant advantage over platinum-based chemotherapy in a phase 3 trial in advanced lung cancer. Key numbers: 432 patients, 73 hospitals in China, phase 3 randomised, double-blind trial. Why it matters: The late-breaking oral presentation at ESMO highlighted the drug's significant advantage over platinum-based chemotherapy in the trial.

Sichuan Biokin Pharmaceutical's anticancer drug iza-bren was presented at the ESMO Congress in Madrid, showing a significant advantage over platinum-based chemotherapy in a phase 3 trial in advanced lung cancer.

The late-breaking oral presentation at ESMO highlighted the drug's significant advantage over platinum-based chemotherapy in the trial.